The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis

INTRODUCTION: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing–remitting (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neurol Ther
Autores principales: Dupuy, Sheena L., Tauhid, Shahamat, Hurwitz, Shelley, Chu, Renxin, Yousuf, Fawad, Bakshi, Rohit
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5130921/
https://ncbi.nlm.nih.gov/pubmed/27744504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-016-0054-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares